Move supports the advancement of next-generation regenerative medicine.

Japan Airlines (JAL) announced the launch of J Solutions Pharma Cells, a specialised cell transport service designed to support advancements in regenerative medicine, a rapidly evolving and critical medical field.

“The rapid growth of regenerative medicine has led to increasing demand for highly specialised cell transport solutions. Leveraging its extensive expertise in pharmaceutical logistics, JAL is committed to driving progress in the medical field by addressing these emerging needs,” says an official release.

Through this service, JAL seeks to contribute to a world where groundbreaking medical treatments for previously challenging diseases – including Parkinson’s disease – are widely and globally accessible, supported by remarkable advances in regenerative medicine such as iPS cell technologies, the release added.

“Cells intended for therapeutic applications have significantly different handling and transport requirements compared to conventional pharmaceuticals. These cells demand rapid, secure and dependable handling. J Solutions Pharma Cell meets these demands with an innovative, customisable transport service that prioritises pharmaceutical-grade care and fast responsiveness.”

JAL has established a robust foundation for high-quality pharmaceutical logistics services, achieving IATA’s CEIV Pharma certification and equipping Narita and Kansai Airports with dedicated pharmaceutical storage facilities, the release added.